FPR3 and breast carcinoma: As shown in Figure 7, the IC50 of Adriamycin on breast cancer cells after FPRL2 knockdown was significantly lower than that of the non-knockdown, both in resistant and non-resistant MCF-7 cells (P < 0.0001) (Figures 6A, B).